Therapeutically targeting RNA viruses via lethal mutagenesis.
RNA viruses exhibit increased mutation frequencies relative to other organisms. Recent work has attempted to exploit this unique feature by increasing the viral mutation frequency beyond an extinction threshold, an antiviral strategy known as lethal mutagenesis. A number of novel nucleoside analogs have been designed around this premise. Herein, we review the quasispecies nature of RNA viruses and survey the antiviral, biological and biochemical characteristics of mutagenic nucleoside analogs, including clinically-used ribavirin. Biological implications of modulating viral replication fidelity are discussed in the context of translating lethal mutagenesis into a clinically-useful antiviral strategy.
Graci
Jason D
JD
PTC Therapeutics, Inc., 100 Corporate Court, South Plainfield, NJ 07080, USA, Tel.: +1 908 912 9249; ; jgraci@ptcbio.com.
Cameron
Craig E
CE